These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 15350938)
21. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908 [TBL] [Abstract][Full Text] [Related]
22. Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma. Abrams RA Cancer J; 2012; 18(6):624-32. PubMed ID: 23187851 [TBL] [Abstract][Full Text] [Related]
23. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662 [TBL] [Abstract][Full Text] [Related]
24. The Virginia Mason approach to localized pancreatic cancer. Picozzi VJ; Traverso LW Surg Oncol Clin N Am; 2004 Oct; 13(4):663-74, ix. PubMed ID: 15350940 [TBL] [Abstract][Full Text] [Related]
25. Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settings. Dickler A; Abrams RA Semin Radiat Oncol; 2005 Oct; 15(4):235-44. PubMed ID: 16183477 [TBL] [Abstract][Full Text] [Related]
26. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382 [TBL] [Abstract][Full Text] [Related]
27. [Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy]. Jensen HA; Nielsen HO; Jensen JD; Fristrup CW; Nielsen M; Pfeiffer P Ugeskr Laeger; 2008 Feb; 170(8):639-41. PubMed ID: 18364156 [TBL] [Abstract][Full Text] [Related]
28. [Surgical results and indications for adjuvant measures in pancreatic cancer]. Beger HG; Büchler MW; Friess H Chirurg; 1994 Apr; 65(4):246-52. PubMed ID: 7912665 [No Abstract] [Full Text] [Related]
29. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen]. Wenger FA; Zieren HU; Jacobi CA; Müller JM Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878 [TBL] [Abstract][Full Text] [Related]
30. [Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery]. Kunitomo K; Kawahito M; Miura M; Komi N Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1342-4. PubMed ID: 2437863 [No Abstract] [Full Text] [Related]
31. Adjuvant chemoradiotherapy in pancreatic adenocarcinoma--are we forcing a milestone? Basu S; Shukla VK Int J Surg; 2011; 9(4):329-31. PubMed ID: 21338719 [TBL] [Abstract][Full Text] [Related]
32. Outcome analysis of pancreaticoduodenectomy at a community hospital. Afsari A; Zhandoug Z; Young S; Ferguson L; Silapaswan S; Mittal V Am Surg; 2002 Mar; 68(3):281-4; discussion 284-5. PubMed ID: 11893108 [TBL] [Abstract][Full Text] [Related]
33. Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? Pisters PW; Evans DB Ann Surg; 2008 Aug; 248(2):152-3. PubMed ID: 18650622 [No Abstract] [Full Text] [Related]
35. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Hughes MA; Frassica DA; Yeo CJ; Riall TS; Lillemoe KD; Cameron JL; Donehower RC; Laheru DA; Hruban RH; Abrams RA Int J Radiat Oncol Biol Phys; 2007 May; 68(1):178-82. PubMed ID: 17276614 [TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy in adenocarcinomas of the pancreas]. Huguier M Gastroenterol Clin Biol; 2002 Nov; 26(11):1063; discussion 1063-4. PubMed ID: 12483149 [No Abstract] [Full Text] [Related]
37. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715 [TBL] [Abstract][Full Text] [Related]
38. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. Mornex F; Girard N; Scoazec JY; Bossard N; Ychou M; Smith D; Seitz JF; Valette PJ; Roy P; Rouanet P; Ducreux M; Partensky C Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1471-8. PubMed ID: 16793214 [TBL] [Abstract][Full Text] [Related]
39. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Wolff RA; Varadhachary GR; Evans DB Ann Surg Oncol; 2008 Oct; 15(10):2773-86. PubMed ID: 18612703 [TBL] [Abstract][Full Text] [Related]
40. Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. van Roest MH; Gouw AS; Peeters PM; Porte RJ; Slooff MJ; Fidler V; de Jong KP Ann Surg; 2008 Jul; 248(1):97-103. PubMed ID: 18580212 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]